Skip to content
Research Article Open access CC BY 4.0

Pathogenesis and Possible Drug Targets for Covid-19

N. Ramesh Kumar, S. Chitra

International Journal of Biochemistry Research & Review · pp. 1–8 · Published 3 Jun 2020

10.9734/ijbcrr/2020/v29i530186

Abstract

Coronavirus (CoVs) is a large family of enveloped, single-stranded, positive-sense RNA viruses that infect a wide range of vertebrates. They are extensively found in bats and also in many other birds and mammals including humans. SARS-CoV-2 is a global pandemic and originated from Wuhan States of China. The SARS-CoV-2 is more genetically similar to zoonotic SARS-CoV and less similar to MERS-CoV.  The viral surface spike protein of SARS-CoV-2 binds to the human angiotensin-converting enzyme-2 (ACE-2) receptor of Type II alveolar cells of the lungs and it appears to be the major portal of entry by this virus.  The subsequent activation of the spike protein by transmembrane protease-2 and in addition to lung, ACE-2 is highly expressed in heart followed by kidney and intestinal epithelium. SARS-CoV-2 infects more men than women due to ACE-2 receptor on the cells increased with age and generally it was higher in men than in women. The incubation period for this virus varies from place to place and asystematic symptoms are also commonly seen in infected patients. There are a number of pharmaceuticals already being tried and are in different phase levels of testing, but a better understanding of the underlying pathobiology is required. In this circumstance, this article will briefly review the underlying principle for ACE-2 receptor as a specific target. Despite ACE-2 serving as the portal for infection, the role of ACE inhibitors or angiotensin receptor blockers requires further investigation.

COVID-19 drug target SARS-CoV-2 ACE-2 TMPRSS-2.

References (28)

  1. 1 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
  2. 2 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
  3. 3 The proximal origin of SARS-CoV-2 [DOI]
  4. 4 COVID-19 and the cardiovascular system [DOI]
  5. 5 Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target [DOI]
  6. 6 Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor [DOI]
  7. 7 Multiorgan and Renal Tropism of SARS-CoV-2 [DOI]
  8. 8 Potential Effects of Coronaviruses on the Cardiovascular System [DOI]
  9. 9 Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein [DOI]
  10. 10 Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer [DOI]
  11. 11 [A pathological report of three COVID-19 cases by minimal invasive autopsies]. [DOI]
  12. 12 TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein [DOI]
  13. 13 Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid Picosecond Laser Treatment for Acquired Bilateral Nevus of Ota – like Macules [DOI]
  14. 14 A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry [DOI]
  15. 15 Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis [DOI]
  16. 16 Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 [DOI]
  17. 17 Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease [DOI]
  18. 18 Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19 [DOI]
  19. 19 Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020 [DOI]
  20. 20 Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak [DOI]
  21. 21 Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS) [DOI]
  22. 22 Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic [DOI]
  23. 23 Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data [DOI]
  24. 24 ACE2: from vasopeptidase to SARS virus receptor [DOI]
  25. 25 Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 [DOI]
  26. 26 Expanding Knowledge of P3 Proteins in the Poliovirus Lifecycle [DOI]
  27. 27 COVID-19 and cardiovascular disease [DOI]
  28. 28 La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

25

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.